• Organizations: Amgen
Real-world TED data finds disease advances beyond acute phase
Research

Real-world TED data finds disease advances beyond acute phase

Real-world study demonstrates heterogeneous disease progression in TED, challenging the traditional self-limited paradigm.
TEPEZZA on-body injector demonstrates positive phase 3 performance for TED
Research

TEPEZZA on-body injector demonstrates positive phase 3 performance for TED

FDA-approved therapy administered subcutaneously met its primary endpoint in demonstrating a statistically significant and clinically meaningful 77% PRR.
FTC approves final consent order following lawsuit against Amgen’s Horizon acquisition
Business

FTC approves final consent order following lawsuit against Amgen’s Horizon acquisition

Commission approves final order consent with major contingencies for Amgen following its October 2023-closed deal.
Amgen's acquisition of Horizon is officially back on
Business

Amgen's acquisition of Horizon is officially back on

FTC and companies agree to resolve antitrust lawsuit filed in May 2023.
Amgen purchase of Horizon delayed after FTC lawsuit
Legal

Amgen purchase of Horizon delayed after FTC lawsuit

Company agrees to push back the transaction date until September 2023 or later; action is a first for the agency.
Amgen is purchasing Horizon Therapeutics
Business

Amgen is purchasing Horizon Therapeutics

Billion-dollar deal is expected to close in early 2023.